Welcome to our dedicated page for Cellectar Biosciences news (Ticker: CLRB), a resource for investors and traders seeking the latest updates and insights on Cellectar Biosciences stock.
Cellectar Biosciences Inc. (NASDAQ: CLRB) is a clinical-stage biopharmaceutical company pioneering targeted cancer therapies through its proprietary Phospholipid Drug Conjugate™ platform. This centralized news resource provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic partnerships.
Access real-time information about CLRB’s radiopharmaceutical pipeline, including lead candidate iopofosine I 131 for hematologic malignancies and emerging programs targeting solid tumors. Our news collection covers critical updates ranging from trial results to manufacturing advancements, all curated to support informed decision-making.
Key content areas include clinical trial progress, FDA designations, scientific presentations, and corporate collaborations. The platform serves as a reliable source for tracking the company’s mission to improve cancer treatment precision through its novel drug delivery technology.
Bookmark this page for continuous access to verified updates about Cellectar’s innovative oncology programs. Check regularly for new developments in targeted radiopharmaceuticals and PDC platform applications across therapeutic areas.
Cellectar Biosciences (NASDAQ: CLRB) and SpectronRx have signed a commercial supply agreement for manufacturing iopofosine I 131, a first-in-class cancer therapy. SpectronRx will produce the treatment at facilities in Indiana and Belgium, supporting Cellectar's planned 2025 commercialization. The drug has shown promising results in the CLOVER-WaM pivotal study for Waldenstrom's macroglobulinemia and is being evaluated in Phase 2 studies for multiple myeloma and CNS lymphoma, as well as a Phase 1b study for pediatric high-grade gliomas. The partnership strengthens Cellectar's global manufacturing network and distribution capabilities.
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on cancer treatment, has scheduled its third quarter 2024 financial results announcement and corporate update for November 18, 2024, at 8:30 a.m. ET. The company will host a conference call accessible via toll-free number 1-800-717-1738 with conference ID 80659, and a webcast will be available. A replay of the call will be accessible through the company's investor relations website.
Cellectar Biosciences (NASDAQ: CLRB) announced that new data from their Phase 2 CLOVER-WaM study of iopofosine I 131 for Waldenstrom's macroglobulinemia (WM) treatment will be presented at ASH 2024. The study focuses on relapsed and refractory WM patients who received at least 2 prior therapies. The company plans to submit a New Drug Application to the FDA in the coming months and will seek priority review. Dr. Sikander Ailawadhi from Mayo Clinic will present the efficacy and safety results during an oral session on December 9, 2024, at the Marriott Marquis San Diego Marina.
Cellectar Biosciences (NASDAQ: CLRB) has regained compliance with Nasdaq Listing Rule 5250(c)(1) following a letter received from Nasdaq on October 31, 2024. The compliance was achieved after the company filed its restated financial statements, including audited consolidated financials for fiscal years 2022-2023, quarterly statements for various periods in 2022-2023, and quarterly financials for 2024 periods. The filings were submitted to the SEC on October 29, 2024, and Nasdaq has confirmed the matter is closed.
Cellectar Biosciences (NASDAQ: CLRB) announced two presentations on iopofosine I 131 at the 12th International Workshop on Waldenstrom's Macroglobulinemia in Prague. The first presentation by Dr. Jorge Castillo will showcase a case study of complete central nervous system clearance in a patient with Bing-Neel Syndrome (BNS), a rare complication of Waldenstrom's Macroglobulinemia (WM). The second presentation by Dr. Andrei Shustov will review topline data from the CLOVER WaM pivotal study, the largest WM study to date in a highly refractory patient population. Iopofosine I 131, Cellectar's lead product candidate, is a potential first-in-class cancer targeting agent that has demonstrated the ability to cross the blood-brain barrier and shown clinical activity in multiple hematologic malignancies involving the central nervous system.
Cellectar Biosciences (NASDAQ: CLRB) has received a delinquency notification from Nasdaq due to a delay in filing its Q2 2024 10-Q report. The delay is caused by the need to restate previously filed financial statements following a re-evaluation of accounting treatment for warrants issued in October 2022. The restatement affects audited financials for 2022-2023 and unaudited quarterly reports from Q1 2023 to Q1 2024.
Cellectar has until October 21, 2024, to submit a compliance plan to Nasdaq. If accepted, Nasdaq may grant an extension until February 17, 2025. The company expects to complete the restatement process in about six weeks, after which it will file the Q2 2024 10-Q. The notice does not currently affect Cellectar's Nasdaq Capital Market listing.
Cellectar Biosciences (NASDAQ: CLRB) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
1. Final data from the CLOVER WaM pivotal study for iopofosine I 131 in Waldenstrom's macroglobulinemia exceeded the primary endpoint with an 80% overall response rate and 56.4% major response rate.
2. The company plans to file a New Drug Application (NDA) for WM in Q4 2024, anticipating a potential launch in 2025.
3. A strategic partnership with City of Hope Cancer Center was announced to evaluate iopofosine I 131 in mycosis fungoides.
4. As of June 30, 2024, cash and cash equivalents were $25.9 million, with an additional $19.4 million raised in July, funding operations into Q2 2025.
5. R&D expenses increased to $8.2 million, and G&A expenses rose to $6.4 million in Q2 2024 compared to the same period in 2023.
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on cancer treatment, has announced it will provide a corporate update for Q2 2024 on Tuesday, August 13, 2024. The company will host a conference call and webcast at 8:30 am Eastern Time to discuss financial results and provide an overview. Investors can join the call toll-free at 1-800-717-1738, and a webcast link is available. A replay of the call will be accessible on the Events section of Cellectar's investor relations website.
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on cancer treatment, has announced it will provide a corporate update for Q2 2024 on Tuesday, August 13, 2024. The update will cover the three months ended June 30, 2024. Management will host a conference call and webcast at 8:30 am Eastern Time to discuss financial results and provide an overview. Investors can join the call toll-free at 1-800-717-1738. A replay of the call will be available on the company's investor relations website.
Cellectar Biosciences (NASDAQ: CLRB) announced positive results from its CLOVER WaM pivotal study evaluating iopofosine I 131 for relapsed/refractory Waldenstrom's macroglobulinemia (WM). The study achieved an 80% overall response rate and a 56.4% major response rate, exceeding the primary endpoint of 20%. Notably, 78% of major response patients remained progression-free at 18 months.
The study included heavily pretreated patients, with 27% refractory to all available therapies and 40% dual-class refractory. Iopofosine I 131 demonstrated efficacy across challenging subgroups and was well-tolerated. Cellectar plans to submit an NDA in Q4 2024, seeking priority review.
FAQ
What is the current stock price of Cellectar Biosciences (CLRB)?
What is the market cap of Cellectar Biosciences (CLRB)?
